Abstract: 2,2-Difluoro prostaglandin E, F.sub..alpha., F.sub..beta., A, and B analogs are disclosed with intermediates and with processes for making them. These compounds differ from the prostaglandins in that they have two fluoro atoms at the C-2 position in place of the two hydrogen atoms at C-2 in the prostaglandins. These compounds are useful for a variety of pharmacological purposes, including antiulcer, inhibition of platelet aggregation, increase in nasal patency, labor induction at term, and wound healing.

Abstract: 2,2-Difluoro prostaglandin E, F.sub..alpha., F.sub..beta., A, and B analogs are disclosed with intermediates and with processes for making them. These compounds differ from the prostaglandins in that they have two fluoro atoms at the C-2 position in place of the two hydrogen atoms at C-2 in the prostaglandins. These compounds are useful for a variety of pharmacological purposes, including antiulcer, inhibition of platelet aggregation, increase in nasal patency, labor induction at term, and wound healing.

Abstract: 2,2-Difluoro prostaglandin E, F.sub..alpha., F.sub..beta., A, and B analogs are disclosed with intermediates and with processes for making them. These compounds differ from the prostaglandins in that they have two fluoro atoms at the C-2 position in place of the two hydrogen atoms at C-2 in the prostaglandins. These compounds are useful for a variety of pharmacological purposes, including antiulcer, inhibition of platelet aggregation, increase in nasal patency, labor induction at term, and wound healing.

Abstract: This disclosure relates to prostaglandins of the PG.sub.3 series including PGE.sub.3, PGF.sub.3.sub..alpha., PGF.sub.3.sub..beta., PGA.sub.3, and PGB.sub.3, to various analogs of those in racemic form, and to novel processes for making those. This disclosure also relates to certain fluorine and alkyl substituted analogs and certain acetylenic analogs of PGE.sub.3, PGF.sub.3.sub..alpha., PGF.sub.3.sub..beta., PGA.sub.3, and PGB.sub.3 in both racemic and optically active form, and to processes for making those. These various analogs are useful for the same pharmacological purposes as the known optically active forms of PGE.sub.3, PGF.sub.3.sub..alpha., PGF.sub.3.sub..beta., PGA.sub.3, and PGB.sub.3, including anti-ulcer, inhibition of platelet aggregation, increase of nasal patency, labor inducement, fertility control, and wound healing.